



Better  
tissue  
leads to  
better  
outcomes





# MTF Biologics exceeds industry standards with stricter donor acceptance criteria.

## Age:

Unlike other tissue banks that may not have an upper age limit for tissue donation, MTF Biologics has lower age limits than most tissue banks and more restrictive age criteria for tissue forms affected by age, such as soft tissue grafts and cell-based, fresh tissue grafts.

## Cancer:

MTF Biologics never accepts donors with a history of metastatic disease, breast cancer, colon cancer, melanoma, hematologic malignancies, metastasizing CNS tumors or any malignancy with an unknown primary site. A history of any other malignancy may be accepted only if there is no recurrence within 5 years of death. We make limited exceptions for in-situ cancer of the cervix and basal cell carcinoma, if surgically removed with no recurrence in 6 months. And, we NEVER accept any malignancy for our fresh tissue grafts.

## End stage renal disease / chronic dialysis:

MTF Biologics defers all musculoskeletal donors with ESRD due to the potential impact on bone and soft tissue quality. In addition, MTF Biologics defers all donors with a history of chronic hemodialysis or peritoneal dialysis.

## Illegal drugs:

Beyond the regulatory requirements of no IV drug use within five years of death, MTF Biologics also rejects non-IV "street drugs" such as cocaine or methamphetamines within 12 months of death and those with drug-seeking behaviors.

## Osteoporosis:

Unlike 50% of other tissue banks, MTF Biologics does not accept donors with medically diagnosed osteoporosis. MTF Biologics defers all donors with a confirmed diagnosis as well as those being treated with bisphosphonates.\*

## Steroids:

Since steroid use can affect tissue quality and safety, MTF Biologics defers all potential donors treated with a dose greater than 20 mg/day for more than 30 days. If the dose and duration is less, donors are reviewed for reason of treatment and potential for osteoporosis or "masked" infection.

At MTF Biologics, we set stricter standards to ensure safety, quality, and better outcomes. Our non-profit organization is led by surgeons and our processes are approved and monitored by a medical board of trustees.

Our mission is to save and heal lives. Our criteria is based on what's best medically, not financially. We encourage you to ask your current tissue bank how their donor selection process compares to ours.

The results may surprise you.

## Ensuring tissue safety in a global pandemic

As a leader in the tissue banking industry, MTF Biologics reacted promptly and effectively in addressing any concerns related to potential risk of tissue transmission of the novel coronavirus or SARS-CoV-2. While there are no known cases of novel coronavirus transmission through transplanted tissue, MTF has taken extra steps to ensure additional safety measures have been implemented. We do not accept donors with a recent medical history or diagnosis of novel coronavirus infection, or with an unexplained clinical syndrome that might be consistent with such infection.

Tissue recipient safety is, and has always been, key to achieving MTF's mission. As a physician-led, science-forward organization, MTF Biologics will continue to be at the forefront of any new developments with novel coronavirus screening.

MTF Biologics  
accepts  
less than 2%  
of donated tissue.\*

**310,180** INITIAL REFERRALS

- **196,887** for age
- **70,977** for medical and/or high-risk behavior
- **12,528** for lack of authorization
- **24,273** for other reasons

**= 5,515** TOTAL RECOVERIES

- **827** for post-recovery rejections

**= 4,688** TOTAL RELEASABLE DONORS

\*This information is based on 2018 data on file at MTF Biologics.

# Compare and see...

## We lead the industry in donor selection criteria.

SCREENING CRITERIA	MTF Biologics	INDUSTRY	FDA
HIV 1/2	X	X	X
Hepatitis B virus	X	X	X
Hepatitis C virus	X	X	X
Illicit drug use, injection drugs (in last 5 years)	X	X	X
Malaria	X	X	X
Sepsis	X	X	X
Syphilis	X	X	X
Transmissible spongiform encephalopathy (TSE)	X	X	X
Vaccinia	X	X	X
West Nile Virus (WNV)	X	X	X
Clinically significant metabolic bone disease*	X	X	
Gonorrhea (clinically active)	X	X	
Leprosy (Hansen's disease)	X	X	
Polyarteritis nodosa	X	X	
Rabies	X	X	
Rheumatoid arthritis*	X	X	
Sarcoidosis	X	X	
Systemic lupus erythematosus*	X	X	
Systemic mycoses	X	X	
Tuberculosis	X	X	
<b>AUTOIMMUNE</b>			
Ankylosing spondylitis **	X		
Autoimmune hemolytic anemia	X		
Autoimmune hepatitis	X		
Guillain-Barre syndrome (clinically active)	X		
Mixed connective tissue disease **	X		
Multiple sclerosis	X		
Myasthenia gravis **	X		
Progressive systemic sclerosis (scleroderma)	X		
Reactive arthritis (Reiter's syndrome) **	X		
Vasculitis	X		
Wegener's granulomatosis (Granulomatosis with polyangiitis)	X		
<b>INFECTION</b>			
Bacteremia/systemic infection	X		
Chagas disease	X		
Encephalitis (clinically active)	X		
Endocarditis (clinically active)	X		
Epstein Barr virus (clinically symptomatic mononucleosis)	X		
Genital herpes (clinically active)	X		
Meningitis (clinically active)	X		
Peritonitis (if bacteremia present)	X		
Pyelonephritis (if bacteremia present)	X		
Varicella-zoster infection (clinically active)	X		
<b>MALIGNANCY*</b>			
Breast cancer	X		
Colon cancer	X		
Hematologic malignancies	X		
Melanoma	X		
Any history of metastatic disease	X		
Unknown primary	X		
<b>OTHER</b>			
End stage renal disease/chronic dialysis **	X		
Osteoporosis **	X		
Steroid treatment (chronic)	X		

\* Not an automatic rule-out for skin donors

\*\* Skin may be acceptable

† Any other malignancy is acceptable if no recurrence within 5 years of death

**Also acceptable:** localized, treated basal cell or squamous cell skin cancer that has not recurred in past 6 months and cervical cancer-in-situ (CIN)